Effect of Antiepileptic Drugs on Bodyweight
- 135 Downloads
The potential of specific antiepileptic drugs (AEDs) to cause clinically significant changes in bodyweight is a key consideration in the management of epilepsy; changes in weight can pose health hazards, impair body image and self-esteem, and lead to noncompliance with therapy. This article reviews the data regarding the effects of conventional and newer AEDs on weight and discusses the clinical implications of these effects for the management of patients with epilepsy. The data demonstrate that AEDs can differ substantially in their effects on weight. Some, such as valproate and carbamazepine, increase weight; others, such as topiramate and felbamate, decrease it. Still others, such as lamotrigine, levetiracetam and phenytoin, are weight neutral.
Because most data regarding the effects of AEDs on weight are circumstantial, the incidence, magnitude and determinants of weight changes with AEDs remain poorly elucidated. Furthermore, little is known about the mechanisms of AED-induced changes in weight.
The importance of effects on weight in selecting an AED depends largely upon the individual patient’s needs and the risks and benefits of therapy for that patient. The most appropriate therapeutic choice is a weight-neutral medication unless circumstances dictate otherwise.
KeywordsWeight Gain Carbamazepine Valproate Gabapentin Lamotrigine
The author thanks Jane Saiers, PhD for assistance with writing this review. Dr Saiers’ work was supported by GlaxoSmithKline, maker of lamotrigine.
Dr Biton has received clinical research grants from Abbott, Élan, GlaxoSmithKline, Hoechst Marion Roussel, Novartis, Ortho McNeil, RWJ Pharmaceutical Research Institute, Pfizer and UCB Pharma. Dr Biton is on the Speaker’s Bureau for Ortho McNeil, GlaxoSmithKline, Novartis, Élan and UCB Pharma. Dr Biton did not receive funding for the preparation of this manuscript.
- 2.Foster D. Gain and loss in weight. In: Fauci S, editor. Harrison’s principles of internal medicine. 14th ed. New York: McGraw Hill, 1998Google Scholar
- 6.Burton BR, Foster WR, Hirsch J, et al. Health implications of obesity: NIH consensus development conference. Int J Obes Relat Metab Disord 1985; 9: 155–69Google Scholar
- 30.Garofalo EA, Hartman T, Hayes A, et al. Weight changes during a gabapentin 26-week monotherapy trial [abstract 6.34]. Epilepsia 1996; 37 Suppl. 5: 160Google Scholar
- 31.King JA, Bayles RL. Weight gain during add-on therapy using gabapentin [abstract 3.60]. Epilepsia 1995; 36 Suppl. 4: 72Google Scholar
- 32.Asconape J, Collins T. Weight gain associated with the use of gabapentin [abstract 3.58]. Epilepsia 1995; 36 Suppl. 4: 72Google Scholar
- 35.Cahill WT, Mozahem K, Privitera MD. Weight changes with the use of gabapentin [abstract 2.090]. Epilepsia 1998; 39 Suppl. 6: 54Google Scholar
- 48.Ben-Menachem E, Smith U, Hellstrom K, et al. Prospective study on metabolism and weight changes in patients with epilepsy treated with topiramate [abstract]. Epilepsia 2000; 41Suppl. 7: 222Google Scholar
- 53.Shuaib A, Ahmad F, Kochanski P, et al. Efficacy of topiramate in prophylaxis of frequent severe migraines or chronic daily headaches: experience with 70 patients over 18 months [abstract]. Cephalalgia 2000; 20: 423Google Scholar
- 54.Von Seggern RL, Mannix LK, Adelman JU. Efficacy of topiramate in prophylactic treatment of migraines in patients refractory to preventative intervention: a retrospective chart review in a tertiary clinic [abstract]. Cephalalgia 2000; 20: 423Google Scholar
- 55.Wilson MC. Efficacy of topiramate in the prophylactic treatment of intractable chronic migraine: retrospective chart review [abstract]. Cephalalgia 2000; 20: 301Google Scholar
- 56.Edwards KR, Glantz MJ, Button J, et al. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study [abstract]. Neurology 2000; 54Suppl. 3: A81Google Scholar
- 62.Felbatol (felbamate) package insert. Cranbury (NJ): Wallace Laboratories, 1999Google Scholar
- 65.Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration. Oxford: Oxford Update Software, 2002: CD001416Google Scholar
- 72.Gidal B, Sheth R, Maganti R, et al. Levetiracetam weight change during placebo-controlled clinical trials [abstract]. Epilepsia 2001; 42Suppl. 7: 157Google Scholar